ESC CONGRESS 2012

25 - 29 August 2012, Munich - Germany

Session Details

Poster session 2: Controversial issues on thrombosic and antithrombotics treatment
Sun 26 Aug 14:00 - 18:00 Antithrombotic agents Poster Session Posters - Village 10

Abstract Slides/e-posters Video Report

List of Presentations

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
14:00P1833Effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in an ex vivo perfusion chamber: an open-label, randomized study in healthy subjectsMichael WOLZT (Wien, AT)
14:00P1834Use of proton pump inhibitors and the risk of coronary events in patients receiving low-dose acetylsalicylic acid in UK primary careLuis Alberto GARCIA RODRIGUEZ (Madrid, ES)
14:00P1835Concomitant administration of antiplatelet agents enhances the antithrombotic effects of rivaroxaban in vitro and in vivoElisabeth PERZBORN (Wuppertal, DE)
14:00P1836Results of the EmbraceAC Trial: a comparison of warfarin to tecarfarin, a novel anticoagulantPeter MILNER (Los Altos Hills, US)
14:00P1837Multiple thrombogenic and atherogenic markers were involved in premature coronary artery diseaseSolange Desiree AVAKIAN (Sao Paulo, BR)
14:00P1838D-dimer, plasmin-antiplasmin complex and matrix metalloproteinase 2 as markers of cardiovascular events in patients with stable coronary disease.Anatoly DOBROVOLSKY (Moscow, RU)
14:00P1839Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing Percutaneous Coronary Intervention.Elisabetta RICOTTINI (Rome, IT)
14:00P1840Combined and independent impact of chronic kidney disease and elevated C-reactive protein on residual platelet reactivityRoxana MEHRAN (New York, US)
14:00P1841Magnetoliposomes for targeting activated platelets: development of a human compatible MRI contrast agent for detection of unstable atherosclerotic plaquesStephanie MEIER (Freiburg, DE)
14:00P1842Hypertriglycerydemia - a predicor of platelet resistance to acetylsalicylic acid in patients with stable coronary artery disease To Be Announced
14:00P1843Blockade of platelet alpha2B-adrenergic receptors: a novel antiaggregant mechanismMary MARKETOU (Heraklion, GR)
14:00P1844High levels of Interleukin-17A and -F are expressed by neutrophils and neutrophil extracellular traps (NETs) in fresh and lytic, but not organized intracoronary thrombusOnno DE BOER (Amsterdam, NL)
14:00P1845Markers of endothelial and platelet activation are associated with high on-aspirin residual platelet reactivityAlf Aage Reistad PETTERSEN (Oslo, NO)
14:00P1846Paraoxonase-1 (PON1) activity is associated with clopidogrel response and intra-stent thrombus after drug-eluting stent implantation in the CYP2C19 loss-of-function polymorphism carriersRyo NISHIO (Kobe, JP)
14:00P1847activation by ADP modulates miRNA expression profile in platelets. new insights into the pathophysiology of platelet activation.Giovanni CIMMINO (Naples, IT)
14:00P1848Optimal thresholds for on-treatment platelet reactivity to predict clinical events after percutaneous coronary intervention are different in patients with and without diabetes mellitusFabio MANGIACAPRA (Roma, IT)
14:00P1849Acute exposure to diesel exhausts induces immediate platelet activation.Aurelien WAUTERS (Bruxelles, BE)
14:00P1850Fibrinogen alpha chain gene variability alters the prothrombotic state independently of risk factors for coronary artery diseaseNikolaos PAPAGEORGIOU (Athens, GR)
14:00P1851Collagen-induced platelet aggregation is specifically suppressed, but coagulation and bleeding time are not altered up to 3 weeks after a single bolus of revacept (dimeric GPVI-Fc; phase I trial)Martin UNGERER (Planegg/Martinsried, DE)
14:00P1852Percutaneous coronary intervention causes increased platelet - derived microvesicle releaseKatarina VARGOVA (Budapest, HU)
14:00P1853Serum- & glucocorticoid-inducible kinase 1 (SGK1) regulates platelet granule biogenesis and secretionOliver BORST (Tuebingen, DE)
14:00P1854High platelet reactivity by arachidonic acid and elevated c-reactive protein levels identify STEMI patients at risk of 5-year follow-up cardiac deathRossella MARCUCCI (Florence, IT)
14:00P1855Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with previous myocardial infarctionErik C L GROVE (Aarhus, DK)
14:00P1856Higher thrombus, altered clot kinetics and fibrin architecture in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome Girish VISWANATHAN (Cardiff, GB)
14:00P1857Bolus administration of PRT064445, a recombinant factor Xa inhibitor antidote, reverses blood loss and PD markers in a rat model following enoxaparin-induced anticoagulation Uma SINHA (South San Francisco, US)
14:00P1858Unlike heparins newer oral anticoagulants do not interact with HIT antibodies and may be useful in the long term anticoagulant management of heparin compromised patientsJawed FAREED (Maywood, US)
14:00P1859In vitro pharmacodynamic effects of EV-077, a new inhibitor of isoprostane and prostanoid cellular activationAntonio TELLO MONTOLIU (Jacksonville Beach, US)
14:00P1860Triple antithrombotic therapy is the independent predictor for the occurrence of major bleeding complications; results from the ICAS registry.Yoshihisa NARUSE (Yokohama, JP)
14:00P1861Association of the cytochrome cytochrome 450 2c19 polymorphism monitoring on residual platelet activity after chronic clopidogrel medication by 3 different platelet function testsMoohyun KIM (Busan, KR)
14:00P1862Current regional differences in the use of antiplatelet drugs for the treatment of acute coronary syndromes. Results from the EPICOR studyHector BUENO (Madrid, ES)
14:00P1863On-treatment platelet reactivity as assessed by multiplate analyser in relation to early and long-term risks for ischemic and bleeding events following the stent placement Cihangir KAYMAZ (Istanbul, TR)
14:00P1864Evaluation of serum fibronectin degradation processes as an additional factor of acute coronary syndromes course defining and development of thrombotic and hemorrhagic complicationsOlena KOVAL (Dnipropetrovsk, UA)
14:00P1865Dual antiplatelet and oral anticoagulant treatment of patients discharged after PCI in acute myocardial infarction - current clinical practice and 12-month outcome - analysis from the PL-ACS RegistryMarek GIERLOTKA (Zabrze, PL)
14:00P1866Warfarin and dual antiplatelet therapy post percutaneous coronary intervention (PCI) in the elderly (>75years old)Gurpreet DHILLON (London, GB)
14:00P1867POPular Risk Score for individualized antiplatelet therapy following non-urgent PCIThomas BERGMEIJER (Nieuwegein, NL)
14:00P1868Management of patients with acute coronary syndromes in the real world practice in italy: an outcome research study focused on the use of antithrombotic agents. the MANTRA registry.Gianni CASELLA (Imola, IT)
14:00P1869Triple versus dual antiplatelet therapy in acute myocardial infarction in relation to renal functionWeon KIM (Seoul, KR)
14:00P1870Sex differences in the management of patients with acute coronary syndromes in the real world practice in Italy: an outcome research study focused on the use of ANTithRombotic Agents. The mantra regisGianni CASELLA (Imola, IT)
14:00P1871Contemporary pre-hospital management of ACS patients: results from the EPICOR studyPeter R SINNAEVE (Leuven, BE)
14:00P1872Despite pharmacological equivalence, generic versions of enoxaparin may differ in their pharmacodynamic actions. Potential clinical implications.Jawed FAREED (Maywood, US)
14:00P1873Reticulated platelets predict the risk of cardiac death in acute coronary syndrome patients independently of mean platelet volume: data from AMI-Florence 2 studyRossella MARCUCCI (Florence, IT)